Drug Trial Radar · NCT01036139
Efficacy and Safety of BF2.649 in Excessive Daytime Sleepiness (EDS) in Parkinson's Disease
Last checked: Nov 19, 2026Latest source record: Apr 12, 2013 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
268
Actual
Start
Dec 2009
Primary completion
Aug 2012
Study completion Aug 2012
Sponsor
- Lead sponsor
- BioprojetAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Dec 21, 2009
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 30 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
To compare the efficacy of BF2.649 over placebo (12 week Double-Blind Phase) and assess the long term safety and the efficacy maintenance(9 months Open-Label Extension Phase) of BF2.649 in the improvement of excessive daytime sleepiness in patients diagnosed with Parkinson's Disease.
Conditions
- Parkinson's Disease
Interventions
BF2.649 (pitolisant)Drug
1 capsule of BF2.649 (5mg, 10mg , 20 mg) O.D
Primary outcomes
What the sponsor says the trial is designed to measure.
- ESS change (Epworth Sleepiness Scale)Time frame: at week 12 / 52 versus baseline
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Pr Arnulf
Paris, France
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.